What it's for (Indications)
- Dutasteride is primarily indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
- It is utilized to improve BPH-related symptoms, reduce the risk of acute urinary retention, and minimize the necessity for BPH-related surgical interventions.
- It can be administered as monotherapy or in combination with an alpha-adrenergic antagonist, such as tamsulosin, to provide enhanced symptom relief and reduction in the clinical progression of BPH.
- The therapeutic benefits of dutasteride, including its ability to shrink the enlarged prostate gland, are generally observed after several months of continuous treatment, reflecting its gradual mechanism of action.
- Its efficacy has been established in long-term studies, demonstrating sustained improvement in urinary flow and a decrease in prostate volume.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of dutasteride for the treatment of benign prostatic hyperplasia (BPH) is one 0.5 mg soft gelatin capsule taken orally once daily. The capsule must be swallowed whole and should not be chewed, opened, or crushed, as contact with the capsule contents may result in oropharyngeal irritation. Dutasteride can be taken with or without food, based on patient preference and convenience. Although some patients may experience improvement in symptoms earlier, a therapeutic trial of at least six months is usually necessary to adequately assess whether a beneficial response to dutasteride has been achieved due to the gradual nature of prostate volume reduction and symptom improvement. Continued treatment beyond this initial period is generally required to maintain the therapeutic effects and prevent symptom recurrence. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects of dutasteride primarily involve sexual function and include decreased libido, erectile dysfunction (impotence), ejaculation disorder, and breast disorders such as tenderness and enlargement (gynecomastia).
- These sexual adverse effects may persist after discontinuation of therapy in some individuals, a phenomenon referred to as post-finasteride syndrome.
- Other less common but notable adverse effects can include dizziness, particularly when dutasteride is co-administered with an alpha-blocker, and various allergic reactions such as rash, pruritus, urticaria, and localized edema.
- More serious, albeit rare, adverse events include prostate cancer of higher Gleason grade (as detailed in the Warnings section) and severe allergic reactions, including angioedema, which requires immediate medical attention.
- Patients should be thoroughly counseled on these potential adverse effects prior to initiating and throughout the course of treatment.
Serious Warnings
- Black Box Warning: As dutasteride does not carry a formal FDA Black Box Warning, the following section outlines 'Serious Warnings' that are crucial for healthcare providers and patients to understand, encompassing critical safety information for this medication. **Serious Warnings:** 1. **Risk of High-Grade Prostate Cancer:** While clinical trials have demonstrated that dutasteride can reduce the overall incidence of prostate cancer, an increased risk of developing high-grade prostate cancer (Gleason score 8-10) has been observed in men treated with 5-alpha-reductase inhibitors. Healthcare professionals should continue to meticulously monitor patients for prostate cancer, acknowledging that the benefits of dutasteride in preventing BPH progression and complications may, in selected patients, outweigh the small increase in risk for high-grade prostate cancer. 2. **Interference with Prostate-Specific Antigen (PSA) Testing:** Dutasteride substantially lowers serum PSA levels. A baseline PSA value should be established prior to initiating treatment. After approximately 6 months of therapy, PSA levels typically decrease by about 50%. This reduction must be diligently considered when interpreting PSA results for prostate cancer screening in treated patients. Any sustained elevation of PSA while on dutasteride, even if values remain within the normal reference range, warrants thorough investigation, including consideration of a prostate biopsy, to rule out prostate cancer. 3. **Teratogenicity and Risk to Male Fetus:** Dutasteride is strictly contraindicated in women who are pregnant or who may become pregnant due to the profound potential for causing severe external genital abnormalities in a male fetus. Dutasteride is absorbed through the skin, and therefore, women who are pregnant or potentially pregnant must not handle dutasteride capsules. If accidental contact with leaking capsules occurs, the affected area should be immediately and thoroughly washed with soap and water. 4. **Blood Donation Restriction:** Men receiving treatment with dutasteride should be advised not to donate blood for a period of at least 6 months following their last dose. This precautionary measure is crucial to prevent the inadvertent administration of dutasteride to a pregnant recipient through transfused blood, which could pose a risk to the developing male fetus.
- Dutasteride significantly affects prostate-specific antigen (PSA) levels, typically reducing serum PSA by approximately 50% after 6 months of continuous treatment.
- This reduction must be meticulously considered when evaluating PSA values for prostate cancer screening; clinicians should effectively double the PSA value for comparison with age-matched normal ranges or establish new baseline PSA values after 6 months of treatment.
- There is an increased risk of developing high-grade prostate cancer (Gleason score 8-10) observed in some clinical trials with 5-alpha-reductase inhibitors, even though the overall incidence of prostate cancer was decreased.
- Dutasteride should not be handled by women who are or may become pregnant due to the significant potential for fetal harm (teratogenicity), specifically affecting the development of external genitalia in a male fetus.
- Men treated with dutasteride should refrain from donating blood for at least 6 months after their last dose to prevent potential exposure to dutasteride through transfused blood, which could harm a pregnant recipient.
- Caution is also advised in patients with hepatic impairment, as dutasteride is extensively metabolized by the liver.
How it Works (Mechanism of Action)
Dutasteride is a potent and selective inhibitor of both type 1 and type 2 isoforms of 5-alpha-reductase, an intracellular enzyme responsible for the conversion of testosterone to dihydrotestosterone (DHT). DHT is recognized as the primary androgen involved in the growth and development of the prostate gland, and consequently, in the pathogenesis of benign prostatic hyperplasia (BPH). By effectively inhibiting both isoforms of 5-alpha-reductase, dutasteride profoundly reduces circulating and intraprostatic DHT levels, leading to a substantial decrease in prostate size, an improvement in urine flow rates, and a significant alleviation of BPH-related symptoms. This dual inhibition provides a more comprehensive and sustained reduction in DHT compared to agents that selectively inhibit only the type 2 isoform. The subsequent reduction in prostate volume helps to relieve the bladder outlet obstruction commonly associated with BPH, improving overall urinary function.
Commercial Brands (Alternatives)
No other brands found for this formula.